Aldatu Biosciences has established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Our proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases. Our pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes.